Login

Unaudited Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
Q2 FY2021
As of Jun 30, 2021
Q1 FY2021
As of Mar 31, 2021
Q4 FY2020
As of Dec 31, 2020
Q3 FY2020
As of Sep 30, 2020
Q2 FY2020
As of Jun 30, 2020
Q1 FY2020
As of Mar 31, 2020
Q4 FY2019
As of Dec 31, 2019
Q3 FY2019
As of Sep 30, 2019
Q2 FY2019
As of Jun 30, 2019
Q1 FY2019
As of Mar 31, 2019
Q4 FY2018
As of Dec 31, 2018
Q3 FY2018
As of Sep 30, 2018
Q2 FY2018
As of Jun 30, 2018
Assets
Current assets
Cash and cash equivalents
Available for sale securities
Prepaid expenses and other current assets
Income tax receivable
Total current assets
Property and equipment, net
Right-of-use asset, net
Income tax receivable, non-current
Other assets
Total assets
Liabilities and Stockholders' Equity
Current liabilities
Accrued research and development expenses
Accounts payable and accrued expenses
Lease liability
Total current liabilities
Lease liability, non-current
Debt, non-current
Total liabilities
Stockholders' equity
Preferred stock—$0.001 par value, 5,000,000 shares authorized, no shares issued or outstanding
Common stock—$0.001 par value, 200,000,000 shares authorized, 137,249,579 and 136,639,687 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income
Total stockholders' equity
Total liabilities and stockholders' equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support